Effects of Stellate Ganglion Block (SGB) on Vasomotor Symptoms in Women Receiving Anti-Estrogen Therapy for Breast Cancer
Phase: PHASE2
Conditions: Hot Flushes, Hot Flashes
Sponsor: Northwestern University

Title:  SGB CA Study
Version August 3, 2018 
Page 1 of 28
Revised Template: November 10, 2014
 
PROTOCOL TITLE:
Effects of Stellate Ganglion Block on Vasomotor Symptoms in Women Receiving   Anti-
Estrogen Therapy for Breast Cancer 
PRINCIPAL INVESTIGATOR:
David Walega, MD, MSCI
Department of Anesthesiology
Northwestern University Feinberg School of Medicine
312-926-9142
d-walega@northwestern.edu
VERSION NUMBER: 5
VERSION DATE: August 3, 2018 
IRB #: STU00200390 Approved by NU IRB for use on or after 3/4/2019 through 3/3/2020.

Title:  SGB CA Study
Version August 3, 2018 
Page 2 of 28
Revised Template: November 10, 2014
Table of Contents
1.0
Objectives .................................................................................................................3
2.0
Background...............................................................................................................3
3.0
Inclusion and Exclusion Criteria ..............................................................................5
4.0
Study-Wide Number of Subjects..............................................................................7
5.0
Study-Wide Recruitment Methods ...........................................................................7
6.0
Multi-Site Research ..................................................................................................7
7.0
Study Timelines........................................................................................................7
8.0
Study Endpoints........................................................................................................7
9.0
Procedures Involved .................................................................................................8
10.0
Data and Specimen Banking...................................................................................14
11.0
Data and Specimen Management ...........................................................................14
12.0
Provisions to Monitor the Data to Ensure the Safety of Subjects...........................17
13.0
Withdrawal of Subjects*.........................................................................................18
14.0
Risks to Subjects*...................................................................................................18
15.0
Potential Benefits to Subjects .................................................................................20
16.0
Vulnerable Populations...........................................................................................20
17.0
Community-Based Participatory Research.............................................................20
18.0
Sharing of Results with Subjects ............................................................................20
19.0
Setting.....................................................................................................................21
20.0
Resources Available ...............................................................................................21
21.0
Prior Approvals.......................................................................................................23
22.0
Recruitment Methods..............................................................................................23
23.0
Local Number of Subjects ......................................................................................24
24.0
Confidentiality ........................................................................................................24
25.0
Provisions to Protect the Privacy Interests of Subjects ..........................................24
26.0
Compensation for Research-Related Injury............................................................25
27.0
Economic Burden to Subjects.................................................................................25
28.0
Consent Process......................................................................................................26
29.0
Process to Document Consent in Writing...............................................................27
30.0
Drugs or Devices ....................................................................................................27
IRB #: STU00200390 Approved by NU IRB for use on or after 3/4/2019 through 3/3/2020.

Title:  SGB CA Study
Version August 3, 2018 
Page 3 of 28
Revised Template: November 10, 2014
1.0
Objectives
 
1.1
Research Aims:
Vasomotor symptoms (VMS) affect up to 65% of breast cancer survivors and 
negatively impact their quality of life. VMS in African American and Latino 
women are significantly more severe as compared to Caucasian women.  
Symptom management should be a priority in Women’s Health research.  Few 
effective treatments for VMS are available. Stellate ganglion blockade (SGB) 
with local anesthetic, previously performed for chronic pain indications, has 
shown promise as a treatment for women with VMS in previous clinical trials, but 
has not been investigated in women with breast cancer receiving anti-estrogen 
therapy in a randomized, sham-control study. 
We aim to evaluate the benefit of SGB in symptomatic women with breast cancer 
seeking relief from moderate to very severe VMS that are adversely affecting 
health and wellbeing.
Scope:  Women with breast cancer on Tamoxifen, aromatase inhibitors or SERMs 
with moderate to very severe VMS will be enrolled as participants in this study.  
Hypotheses:  
The frequency and intensity of subjective and objective VMS will be significantly 
lower in women randomized to active SGB as compared to sham controls. Mood, 
memory, cognition, sleep, and quality of life will all be improved in the treatment 
group as compared to the sham-control group.
Specific Goals and Objectives:  
Goal 1: To determine the effect of stellate ganglion blockade (SGB) for reducing 
subjective and objective VMS in women with breast cancer on tamoxifen, AIs, or 
SERMs 
                              
Goal 2: To evaluate the effect of SGB on mood, memory, cognition, sleep and 
quality of life in women with breast cancer on tamoxifen, AIs, or SERMs.                                            
Goal 3: Using the results of this pilot study, we plan to submit an R01 grant to the 
National Cancer Institute for a larger scale study.
2.0
Background
IRB #: STU00200390 Approved by NU IRB for use on or after 3/4/2019 through 3/3/2020.

Title:  SGB CA Study
Version August 3, 2018 
Page 4 of 28
Revised Template: November 10, 2014
VMS (hot flashes and night sweats) are common in women with breast cancer in 
those treated with tamoxifen, aromatase inhibitors, selective estrogen receptor 
modulators (SERMs) and other chemotherapy1-6. To many of these women, these 
symptoms are severe and intolerable, with a significant decrease in quality of 
life4.  VMS are also more common in African American and Latino women3.  
Most importantly, VMS may be a factor in premature discontinuation of anti-
estrogens therapy for women with breast cancer.
2.1
 
Describe any relevant preliminary data.
Uncontrolled studies have demonstrated improvements in the frequency and intensity 
of VMS following stellate ganglion blockade (SGB) with local anesthetic, with 
effects ranging from 45-90% reduction for 6 weeks to several months8-10. These same 
studies showed improvements in sleep quality as well.  
The stellate ganglion is a neural structure in the anterior cervical spine region and is 
part of the sympathetic nervous system.  It has been injected safely in the practice of 
pain management for more than 50 years in cases of post herpetic neuralgia 
(shingles), complex regional pain syndrome (CRPS) and other painful neuropathies. 
Prior studies have confirmed connections between the stellate ganglion and the 
insular cortex and hypothalamus via third order neurons.
2.2
Describe the relevant prior experience and gaps in current 
knowledge
We recently published a prospective, randomized, sham controlled study of SGB in 
women with natural or surgical menopause, in which we found a 52% decrease in 
moderate to very severe VMS in women who underwent a single SGB with 
bupivacaine, a local anesthetic, as compared to a 4% decrease in women in the sham 
control group who underwent an injection of saline11. We also identified statistically 
significant improvements in objective hot flashes, measures of verbal learning and 
trends toward improved depression in the SGB treatment group, whereas such 
beneficial effects were not seen in the sham control group. 
Only one controlled study of SGB in women with breast cancer has been published to 
our knowledge14. Patients with at least one month of VMS underwent either an 
image-guided stellate ganglion injection at the C7 level with 0.5% bupivacaine 10mL, 
or were prescribed pregabalin, a membrane stabilizer found to diminish vasomotor 
symptom in some patients, at 75 mg twice daily, and were followed for 3 months. 
Participants recorded the intensity and frequency of hot flashes in a diary. Both 
treatment groups were observed to have considerable reductions in frequency and 
intensity of VMS, but there was no control group in the study design and the 
randomization method was not described14.  As it is well known that the placebo 
effect in hot flash studies can be dramatically high, more than 60% in some reports15, 
it is important to use a study design that evaluates the placebo effect of any treatment.  
IRB #: STU00200390 Approved by NU IRB for use on or after 3/4/2019 through 3/3/2020.

Title:  SGB CA Study
Version August 3, 2018 
Page 5 of 28
Revised Template: November 10, 2014
Our prior work demonstrated a significant treatment effect with SGB for VMS. In 
addition to the fact that VMS are typically more severe and bothersome in breast 
cancer patients, VMS symptoms can be a factor in patients stopping breast cancer 
treatment. We feel it is important to study the effects of SGB in this patient 
population using a randomized sham-control study design.
2.3
Provide the scientific or scholarly background for, rationale for, 
and significance of the research based on the existing literature and how 
will it add to existing knowledge
Very few effective treatments are available for VMS, and racial and socioeconomic 
disparities significantly decrease access to treatments that are available. Although 
hormone therapy (HT) remains a highly effective treatment for VMS in some 
menopausal women, HT is contraindicated in breast cancer patients, breast cancer 
survivors, and those at risk of breast cancer or other hormone sensitive malignancies.  
Non pharmacologic treatments like botanicals, acupuncture, yoga, and lifestyle 
interventions have shown little to no improvements in VMS symptoms in clinical 
trials. Although Brisdalle (Paroxetine, an anti-depressant) was recently approved by 
the FDA in 2013 for the treatment of VMS in menopausal women, fairly low efficacy 
of this therapy as compared to placebo is seen and intolerable side effects are 
attributed to this class of drugs (weight gain, decreased libido and anorgasmia).
The exact mechanism of SBG is not fully understood. Treatment with SGB is based 
on the interruption of the sympathetic nervous system, changes in blood flow and 
modulation of norepinephrine (NE) levels or nerve growth factor (NGF) in the 
thermoregulatory regions of the brain. As well, remodeling or modulation of neural 
receptor systems or feedback systems involving the stellate ganglion and the insular 
cortex, the thermoregulation and homeostatic control centers in the brain115, 16 are 
likely being affected.
  
In this study, we aim to assess the effects of SGB on subjective and objective VMS, 
mood, memory, cognition, sleep and quality of life in women with breast cancer using 
tamoxifen, aromatase inhibitors or SERMS in a prospective, randomized, sham-
control study, with a six month follow up.
3.0
Inclusion and Exclusion Criteria
3.1
Describe how individuals will be screened for eligibility.
Patient entry, exclusion and dropout criteria:
a. General inclusion criteria include
1. aged 30 to 75 years
2. 28 or more reported moderate-to-very severe hot flashes 
per week 
3. a minimum of two weeks of VMS diary recording prior to 
SGB
4. current use of tamoxifen, aromatase inhibitors, or SERMs 
for a breast cancer indication for at last six months 
IRB #: STU00200390 Approved by NU IRB for use on or after 3/4/2019 through 3/3/2020.

Title:  SGB CA Study
Version August 3, 2018 
Page 6 of 28
Revised Template: November 10, 2014
5. willingness to undergo fluoroscopy-guided SGB or sham 
treatment. 
6. if participant is on an SSRI or SNRI, they must be on a    \ 
      stable dose of SNRI or SSRI for previous six month
            7. approval of treating psychiatrist or psychologist to           
                participate in study if  Depression and Anxiety Scale Score      
                (DASS) score is ≥ 21 for depression or ≥15 for anxiety    
         
b. General exclusion criteria include: 
1. conditions that preclude SGB or sham intervention (e.g., 
anatomic abnormalities of the anterior neck or cervical 
spine; goiter, cardiac/pulmonary compromise; acute 
illness/infection; coagulopathy or bleeding disorder; 
allergic reactions/contraindications to a local anesthetic or 
contrast dye); 
2. use of treatments in the past two months that can affect 
VMS (e.g., use of oral or transdermal HT or contraceptives, 
3. conditions or disorders that can affect performance on 
cognitive tests (e.g., dementia/mild cognitive impairment; 
stroke; traumatic brain injury; alcohol/substance use; 
inability to write, speak, or read in English, English as a 
second language
                                           4 Mini-Mental State Exam (MMSE) ≥ 28
                               5.  conditions that can affect sleep quality (e.g., use of sleep 
agents; shift work; etc.)
3.2
Describe the criteria that define who will be included or excluded 
in your final study sample.
After participants have reviewed and signed the consent form in person, they will be 
interviewed to determine candidacy for the study. They will be asked to provide 
information about themselves and their medical history. Before the intervention 
procedure, they will be asked to maintain a diary of VMS. Participants will be instructed 
to record the frequency and severity of each hot flash or night sweat using the following 
definitions: “mild” (< 5 minutes, warm, red face, uncomfortable), “moderate” (< 15 
minutes, warmth involving neck, ears, head, whole body, with perspiration, clammy skin, 
dry mouth, tense muscles, tachycardia, irritation, agitation, embarrassment), “severe” (< 
20 minutes, warmth described as a raging furnace or burning up, weak, faint, headache, 
chest heaviness, extreme perspiration, prickling sensation over skin, heart irregularities, 
anxious, panic attacks) or “very severe” (< 45 minutes, boiling eruption, rolling 
perspiration, inability to breathe, faint/dizzy, leg/foot cramps, heart irregularities, 
difficulty functioning, distressed, nausea). They will be asked to do this for a minimum of 
two weeks prior to the procedure in order to determine eligibility for the study. VMS 
eligibility will be re-assessed 24 hours before the SGB. A participant will not be 
permitted to proceed with the initial procedure if they do not have the completed written 
IRB #: STU00200390 Approved by NU IRB for use on or after 3/4/2019 through 3/3/2020.

Title:  SGB CA Study
Version August 3, 2018 
Page 7 of 28
Revised Template: November 10, 2014
baseline diary for a confirmatory VMS frequency and severity count at the time of the 
procedure.
To screen for depression, we will use the Depression Anxiety and Stress Scale (DASS). 
Women excluded on the basis of their DASS (≥ 21 for depression and ≥15 for anxiety) 
scores will be referred to a mental health provider. 
To screen for dementia, we will administer the Mini-Mental State Exam (MMSE).  
Women with an abnormal or low MMSE score (MMSE ≥ 28) will be referred to a health 
provider.
3.3
Indicate specifically whether you will include or exclude each of 
the following special populations:
The following special populations will not be included in this 
research:

Adults unable to consent

Individuals who are not yet adults (infants, children, teenagers)

Pregnant women

Prisoners
4.0
Study-Wide Number of Subjects-NA
5.0
Study-Wide Recruitment Methods-NA
6.0
Multi-Site Research-NA
7.0
Study Timelines
7.1The duration of an individual subject’s participation in the study
Subjects will participate in this research study for at least seven months. They 
have the option of recording hot flashes on a paper diary for an additional six 
months after the study ends. If they elect to do this, their participation will last at 
least thirteen months.
            
              7.2 The duration anticipated to enroll all study subjects
We expect to complete enrollment within twelve months.
   
   7.3 The estimated date for the investigators to complete this study 
We expect to complete the study in approximately 1.5 to 2.0 years.
8.0
Study Endpoints
8.1
Describe the primary and secondary study endpoints.
Primary Outcome/Endpoint: reduction in frequency and intensity of      
VMS subjective hot flashes that have been recorded on a paper diary for the duration of 
the study.
IRB #: STU00200390 Approved by NU IRB for use on or after 3/4/2019 through 3/3/2020.

Title:  SGB CA Study
Version August 3, 2018 
Page 8 of 28
Revised Template: November 10, 2014
            
Secondary outcomes/endpoint: Changes in the following measures from baseline, 3 
months, 6 months:
Objective hot flashes as measured over a 24-hour period with a validated skin       
conductance monitor
Memory: Mini-Mental State Exam (MMSE)
Mood: Depression Anxiety and Stress Scale (DASS) and Center for Epidemiological 
Studies-Depression (CES-D)  
Cognition: Neurocognitive testing: California Verbal Learning Test (CVLT),List A, List 
B, List A Short-Delay Free Recall, List A Short-Delay Cued, Recall, List A Long Delay 
Free Recall, Long Delay Cued Recall, Card Rotation Tests, Digit Span (Forward and 
Backward), Benton Visual Retention Test,(BVRT), Finding As, Brief Test of Attention 
(BTA) Numbers, Brief Test of Attention (BTA) Letters, Logical Memory Subtest of 
Wechsler Memory Scale, Revised (WMS-R/LM-R), Letter, Semantic and Phonemic 
Fluency) Baseline and 3 months only.
QOL: Functional Assessment of Cancer Therapy-Breast (FACT-B McCoy             
Female Sexuality Questionnaire (MFSQ)),
Sleep: Pittsburg Sleep Quality Inventory (PSQI), Actigraphy changes in sleep    
Quality 
8.2
Describe any primary or secondary safety endpoints
Before the procedure, a medication line will be inserted into a vein in the subject's arm. 
An oxygen monitor and blood pressure cuff will also be placed. Subjects will be 
positioned on their back for this procedure. Their neck will be swabbed with disinfectant 
to clean the skin, and sterile equipment and technique will be used for the entire of the 
procedure.
After the study procedure is completed, subjects will stay in the office for half an hour for 
observation. Blood pressure will be checked. All subjects will have a peripheral 
intravenous catheter (a plastic tube to take blood and give medicines without having to 
stick the vein multiple times) placed in their arm prior to the procedure, and temperature 
monitoring of the arm and hand, evaluation for temporary drooping of the right eyelid, 
redness in the eye, congestion in the nose, and sweating on the right side of the face will 
be performed.  These confirmatory signs of proper SGB placement will not be recorded 
as AEs. 
The study team will meet and review all adverse events after five subjects have been 
randomized and received the SGB procedure or sham. Per NU IRB protocol, all 
UPIRSO's or PRNCs will be reported a soon as the PI becomes aware of it. As the PI is 
the injectionist, the likelihood of missing a UPIRSO is highly unlikely. If no 
SAEs/UPIRSO's are observed, the team will meet again after 10 subjects have been 
randomized. No UPIRSOs or SAEs have occurred in previous studies. 
 
9.0
Procedures Involved
9.1
 Describe and explain the study design.
IRB #: STU00200390 Approved by NU IRB for use on or after 3/4/2019 through 3/3/2020.

Title:  SGB CA Study
Version August 3, 2018 
Page 9 of 28
Revised Template: November 10, 2014
We aim to conduct a randomized, single-site, sham-control clinical trial of SGB on VMS 
in 36 women with breast cancer on anti-estrogen therapy (18 per group).  We will need to 
screen and enroll approximately 50 women to randomize 36 women. Some women may 
not qualify due to insufficient number of hot flashes or there may be some withdrawals.   
The primary entry criterion will be 28 or more moderate to very severe hot flashes per 
week. VMS will be measured by self-report on a written daily dairy over a 6-month 
period. Secondary outcomes include changes in mood, sleep, quality of life, memory 
performance with neurocognitive testing, and objective hot flashes measured by 
ambulatory monitoring (skin-conductance temperature monitoring) for 24 hours at 
baseline, three months and six months.
Randomization and Masking Procedures A computer-generated 1:1 block randomization 
scheme will be used to assign participants to receive either a SGB with bupivacaine or a 
sham injection with saline. Randomization will be performed by the injectionist 
immediately before the injection procedure by opening an opaque envelope to reveal the 
participant number and group assignment printed on an index card. Randomization 
assignment will be kept under lock and key. Participants and all other study personnel, 
including those who will perform follow-up evaluations, will be blinded to group 
assignment. The injectionist will not have access to the written VMS diaries until the 
conclusion of the study.
9.2
Provide a description of all research procedures being performed and when 
they are performed, including procedures being performed to monitor subjects for 
safety or minimize risks.
Screening Visit 1
Recording of Hot Flashes
After the participant has reviewed and signed the consent form, they will be interviewed 
to determine if they are a candidate for the study. We will ask them to provide 
information about themselves and their medical history. A member of the study team will 
administer the Depression Anxiety and Stress Scale (DASS) to ensure that participants 
are not suffering from extreme anxiety or depression. If they are found to have any of 
these conditions and meet the exclusion criterion, they will not qualify for our study and 
will be referred to a mental health provider.
Before having the SGB procedure participants will be asked to maintain a daily paper 
diary of their hot flashes, recording the number and severity using a scale that will be 
provided to them. They will be asked to do this a minimum of two weeks prior to the 
SGB procedure in order to determine if they are eligible for the study. They will also 
record any comments about the hot flashes they experience each day. 
At the end of two weeks, a member of the study team will telephone to ask how many hot 
flashes they are experiencing in a week. If they qualify based on the total number of hot 
flashes, they will be scheduled to return to the research office for placement of the hot 
IRB #: STU00200390 Approved by NU IRB for use on or after 3/4/2019 through 3/3/2020.

Title:  SGB CA Study
Version August 3, 2018 
Page 10 of 28
Revised Template: November 10, 2014
flash monitor, actigraph watch, questionnaire completion and cognitive testing 
procedures which are described separately. 
The study procedure with Dr. David Walega in the Department of Anesthesiology will be 
scheduled to occur at a separate visit.
Visit 2   (2 to 3 weeks after visit 1)  
There are four types of research evaluations that they will be asked to complete: 
questionnaires, hot flash monitoring, actigraph watch monitoring and tests of mental 
abilities (cognitive testing). They will be asked to complete these four tasks at three time 
points: before the procedure, three months after the procedure, and six months after the 
procedure. Below we describe each of these types of research evaluations.
Cognitive Testing
They will be asked to complete some memory functioning tests that will assist us in the 
evaluation of the results of the study procedure. At each session, they will meet one-on-
one with a research assistant who is trained in giving tests of different mental abilities. 
That assistant will instruct the participant on how to complete tasks that measure different 
mental abilities, such as memory, concentration, and language. Assessment of cognitive 
function has certain exclusion criteria. If they are found to be ineligible to participate in 
this portion of the study, they may still participate in the hot flash portion of the study.
Questionnaires
They will also complete questionnaires about mood and everyday functioning. They may 
refuse to answer any question that they don’t wish to answer. If they become 
uncomfortable at any time and wish to stop, the tests will be
stopped. These forms are:

Depression Scale (CES-D)

Depression Anxiety and Stress Scale (DASS)

Mini-Mental State Exam (MMSE)

McCoy Female Sexuality Questionnaire (MFSQ)

Modified Pittsburgh Sleep Quality Index (PSQI)

Functional Assessment of Cancer Therapy (FACT-B)

Pain Intensity and Interference Scale (PEG)
Hot Flash Monitoring
A research assistant will attach a hot flash monitor to the participant after they have 
completed the above mentioned. The hot flash monitor will be returned 24-hours later to 
the office via UPS or, at their convenience, a research assistant can meet them to 
disconnect and collect the hot flash monitor at their doctor's office or back at the study 
site. 
IRB #: STU00200390 Approved by NU IRB for use on or after 3/4/2019 through 3/3/2020.

Title:  SGB CA Study
Version August 3, 2018 
Page 11 of 28
Revised Template: November 10, 2014
The hot flash monitor we are using in this study is a small, lightweight, portable recorder 
that measures how many hot flashes you have each day. The monitor includes some wires 
and adhesive pads. The adhesive pads are attached to the skin on the chest just below the 
collarbones. Inside each adhesive pad is a small device that measures hot flashes. Wires 
send signals from the device to the monitor. Occasionally, the device may malfunction if 
the adhesive loosens or for other unknown reasons. Should this occur, they may be asked 
to wear the monitor for an additional 24 hours in order to collect missing objective hot 
flash data. The monitor measures 1 x 4 x 6 inches and weighs 8 ounces. The monitor is 
carried in a bag that is worn around the waist like a fanny pack. They will be given verbal 
instructions and handouts describing how to use the monitor. 
Actigraph Watch
The research assistant will also instruct the participant on how to wear an Actigraph. An 
Actigraph is worn just like a watch and monitors sleep and wake habits. It should be 
removed for bathing, showering or swimming. They will be given verbal instructions and 
handouts describing how to use the actigraph watch. They will be given a prepaid return 
mailing box so that they can return the hot flash monitor and the Actigraph to us via UPS.
Visit 3 (4-5 weeks after visit 1)
Stellate Ganglion Injection Procedure
Participants will be interviewed to assess health status and a brief physical exam will be 
performed by Dr. Walega. If they are determined to be a candidate for the procedure by 
Dr. Walega, will randomize the participant into one of two groups: one group will receive 
the study procedure (stellate ganglion injection with local anesthetic or numbing 
medication) and the other will receive a sham procedure involving a saline injection in 
the superficial tissues of the right side of the neck in the region just below the skin layer. 
Assignment to groups will be done by randomization similar to flipping a coin. They will 
have a 50% chance of going into either of the two groups. The study will be single 
blinded. Participants will not know which group they are in and only Dr. Walega will 
know whether they have received the stellate ganglion injection with numbing 
medication or the sham injection with saline. Since it is unknown how long the effects of 
the injection on hot flashes lasts, participants will have the option of receiving a second 
injection after the three month procedures if they notice an increase in the severity or 
frequency of their hot flashes. They will receive the same injection (bupivicaine or sham) 
that they got at the beginning of the study.  
Before the procedure, a medication line will be inserted into a vein in the arm. An oxygen 
monitor and blood pressure cuff will also be placed. They will be positioned on their back 
for this procedure. Their neck will be swabbed with disinfectant to clean the skin, and 
sterile equipment and technique will be used for the entire of the procedure.
With the use of a low dose x-ray machine (fluoroscopy machine) to help guide the 
injection, a bone in the right side of the neck (C6) will be identified and local anesthesia 
or numbing medicine (1% lidocaine) will be injected to the skin overlying the bone. 
IRB #: STU00200390 Approved by NU IRB for use on or after 3/4/2019 through 3/3/2020.

Title:  SGB CA Study
Version August 3, 2018 
Page 12 of 28
Revised Template: November 10, 2014
For subjects receiving the stellate ganglion injection, a small needle will be placed 
through the numbed skin on the front of the right side of the neck to make contact with 
the tissues over the C6 (neck) bone. The correct position of this needle will be confirmed 
by injecting a small amount of dye that can be seen by Dr. Walega under x-ray. Then 10 
cc or about 2 teaspoons of 0.5% bupivicaine (numbing medicine) will be injected and the 
needle will be removed.  
In participants put in the sham injection group, the needle will be placed in the superficial 
tissues overlying the front right neck (C6 bone), just underneath the skin. 5 cc of saline 
fluid will be injected and the needle will be removed.  This procedure will take a few 
minutes. After it is completed, they will stay in the office for about half an hour for 
observation. Their blood pressure will be checked. 
As above, all subjects will have a peripheral intravenous catheter (a plastic tube to take 
blood and give medicines without having to stick the vein multiple times) placed in their 
arm prior to the procedure, and temperature monitoring of the arm and hand, evaluation 
for temporary drooping of the right eyelid, redness in the eye, congestion in the nose, and 
sweating on the right side of the face will be performed. 
Visit 4 (3 months after study procedure)
They will be asked to return to the clinical site 3 months following the injection 
procedure. At this visit, the same procedures listed in visit 2 will be performed.
Visit 5 (6 months after study procedure)
They will be asked to return to the clinical site 6 months following the injection 
procedure. At this visit, the same procedures except for cognition testing listed in visit 2 
will be performed.
Participants will continue to complete their hot flash diary for the duration of the study. 
Their part in this study will last for approximately seven months and will involve five 
visits.
Additional Follow Up (6-12 months after study procedure)
Participants will be asked if they have any interest in maintaining a paper diary for an 
additional six months to assess longer term effects of the treatment. If they agree, a 
member of the research staff will call once a month for the next six months and to remind 
them to complete their hot flash diary and record long term effects, if any.
If they choose to continue to record their hot flashes, their participation may increase to 
thirteen months and they will have 6 visits.
9.3
Describe:

Procedures performed to lessen the probability or magnitude of risks. 
At the time of the injection procedure, an angiocatheter will be placed in the left 
hand/arm for peripheral intravenous access as a safety precaution and a temperature 
monitor will be placed on the right dorsal hand. Participants will be positioned supine in 
cervical extension. The anterior neck will be prepped with chlorhexidine and draped in 
IRB #: STU00200390 Approved by NU IRB for use on or after 3/4/2019 through 3/3/2020.

Title:  SGB CA Study
Version August 3, 2018 
Page 13 of 28
Revised Template: November 10, 2014
the standard sterile manner. For active SGB, a right-sided SGB will be performed. Using 
fluoroscopic guidance, the C6 vertebra will be identified and the skin overlying the 
tubercle will be anesthetized using 2 mL of 1% lidocaine. Using digital pressure to 
laterally retract the carotid artery, a 22 g 1.5-inch needle will be placed to make contact 
with the anterolateral portion of the C6 vertebra and then retracted 1-2 mm and secured; 
contrast material (iopamidol 1-2 mL) will be injected with fluoroscopic guidance to 
confirm contrast dye spread in the prevertebral fascial plane and to rule out intravascular 
or intrathecal dye spread. 0.5% bupivacaine (10 mL) will be injected and the needle will 
be removed. Generally, any woman can safely have this injection unless she has an 
allergy to local anesthetic, contrast material, or has anatomic abnormalities of the anterior 
neck, all of which are rare. Drug interactions are a concern with other non-hormonal 
treatments for VMS, but not with SGB. The dose of local anesthetic needed to block the 
stellate ganglion does not cause toxic plasma levels of local anesthetic in the bloodstream 
and does not significantly interact with medications used for hypertension, asthma, 
depression, or seizures.
For sham injection, the same positioning, monitoring, sterile preparation and technique 
will be used with identical visual, auditory and tactile cues, except the needle will be 
placed in the superficial tissues overlying the C6 tubercle. With fluoroscopic guidance, 
contrast material (iopamidol 1-2 mL) will be injected to confirm contrast dye spread in 
the subcutaneous tissues, not in the prevertebral fascial plane of the stellate ganglion. 
Preservative-free saline (5 mL) will be injected and the needle will then be removed. 
Participants will be transferred to a recovery area and monitored in a reclining position 
for at least 20 minutes to assess potential adverse effects of the injection. Vital signs will 
be measured every 5 minutes during the recovery phase. Presence of a Horner’s sign 
(miosis, ptosis, anhydrosis) will be recorded and will validate successful SGB. Pre- and 
post-injection temperatures of the right hand will be measured and recorded. The research 
team will not have access to the injectionist's procedure notes in order to maintain the 
blind. Miosis, ptosis, and anhydrosis will not be considered adverse events as they are 
confirmatory for adequate SGB placement.

All drugs and devices used in the research and the purpose of their 
use, and their regulatory approval status. 
The study will use approved drugs (0.5% Bupivacaine, 1% Lidocaine and sterile saline) 
for unapproved uses (reduction in VMS). The package inserts have been uploaded into 
the "Supporting Documents" section of the IRB application.

The source records, including medical or educational records that 
will be used to collect data about subjects. (Attach all surveys, scripts, and data 
collection forms.)
Copies of all surveys, diaries, subject instructions, cognition testing battery and data 
collection forms have been uploaded under the" Supporting Documents" section of the 
IRB application.
9.4
What data will be collected, including long-term follow-up.
Baseline data for subjective VMS frequency and severity will be recorded by
IRB #: STU00200390 Approved by NU IRB for use on or after 3/4/2019 through 3/3/2020.

Title:  SGB CA Study
Version August 3, 2018 
Page 14 of 28
Revised Template: November 10, 2014
participants in a written diary. Additional data for depression, sleep, fatigue, sexual 
health, quality of life, and cognitive function will be recorded, along with 
sociodemographic information related to the study participants in
a case report form (see Participant Booklet in "Supporting Documents" section of IRB). 
The research chart and Case Report Form (CRF) will be maintained in the research office 
of Dr. Walega.
9.5
For HUD uses provide a description of the device, a summary of how you 
propose to use the device, including a description of any screening procedures, the HUD 
procedure, and any patient follow-up visits, tests or procedures. N/A
10.0
Data and Specimen Banking-N/A
10.1
If data or specimens will be banked for future use, describe where the specimens 
will be stored, how long they will be stored, when they will be destroyed (if ever), how the 
specimens will be accessed, and who will have access to the specimens.
10.2
List the data to be stored or associated with each specimen.
10.3
Describe the procedures to release data or specimens, including: the process to 
request a release, approvals required for release, who can obtain data or specimens, and 
the data to be provided with specimens, including whether those data will be identifiable 
to others.
11.0
Data and Specimen Management
11.1
Describe the data analysis plan, including any statistical procedures. 
Subjective VMS: As described in the determination of eligibility based on VMS entry 
criteria section for six months following the intervention, intensity of daytime VMS will 
be calculated as follows: Intensity = Frequency*Severity = [(frequency of mild*1)+ 
(frequency of moderate*2) + (frequency of severe*3) + (frequency of very severe*4)] and 
used as a secondary endpoint. Frequency of night sweats will also be recorded daily via 
self-report the following morning. Baseline VMS frequency will be calculated as the 
mean of the daily count totals on diaries during the first two screening weeks. VMS 
frequency at Months 1 to 6 will be calculated as the mean of the daily count totals 
reported for the 30 days before each visit.
Objective VMS: At baseline, and the 3- and 6-month post-intervention visits, 
participants will complete a second measure VMS objectively using the ambulatory 
sternal skin conductance monitor (Biolog Model 3991 x/2-HFI). Raw objective hot flash 
data will be analyzed by a combination of automated computer software and two trained 
data coders. According to standard procedures, once an objective hot flash will be coded, 
no other VMS will be coded for the next 15 minutes. Data will be independently double-
scored and double-entered into the database by coders blinded to treatment assignment. 
Participant sensitivity to objective HF will be calculated by dividing the total number of 
true positive hot flashes (i.e., objectively determined hot flashes that were subjectively 
detected) by the sum of the  total number of objectively measured hot flashes (i.e., true 
positives and false negatives). Primary outcome measures will be total objective and 
subjective hot flashes in a 24-h period, during waking hours, and during sleeping hours. 
IRB #: STU00200390 Approved by NU IRB for use on or after 3/4/2019 through 3/3/2020.

Title:  SGB CA Study
Version August 3, 2018 
Page 15 of 28
Revised Template: November 10, 2014
Baseline characteristics: (e.g., sociodemographic variables, primary and secondary 
outcomes) will be compared between treatment groups using t-tests or chi-square tests for 
categorical variables. Multiple types of measurement outcomes (frequencies, counts, 
continuous and incidence outcomes) will be collected in this study. We will conduct 
intent-to-treat (ITT) analyses for all primary and secondary outcomes using a series of 
generalized mixed-effects regressions as described below. All statistical tests will be two-
sided with significance set at p≤.05. SAS statistical software version 9.2 (SAS Institute 
Inc., Cary, NC, USA) will be used for statistical analyses. In preliminary analysis, the 
distributional aspects of the variables under consideration will be examined through 
descriptive statistics. These statistics will include measures of location (mean, median, 
quartiles) and measures of dispersion (range, standard deviation, variance) for continuous 
variables and frequencies of the levels of categorical variables. These measures will also 
assist with a data cleaning/screening procedure to eliminate any possible copying, 
handling, recording or measurement errors.
In addition to the features described above, the dependence of outcome measures will 
need to be properly accounted for in the data analysis as measures will be made at 
multiple times for the same participant. Consequently, these observations tend to be 
correlated and require statistical techniques that can properly account for the correlation 
in order to draw valid inference. Our general approach for analyzing these multiple types 
of data in this trial will be the Generalized Linear Mixed-Effect Models (GLMM). These 
models can accommodate a wide range of outcomes including normal, binary, ordinal, 
and Poisson outcomes, while taking into account correlations from within-subject 
observations. To study the changes in outcomes over time and to evaluate group 
differences in these changes, we will construct GLMM models. The main independent 
variables in statistical model specifications typically include the group indicator, dummy 
variables for time, and the interactions between them, after controlling for observed and 
relevant covariates. By properly constructing GLMMs, a wide range of scientific 
hypotheses can be tested, including cross-sectional differences among groups, the effect 
of treatment over time and differences between groups over time.
Data will be analyzed using the PROC MIXED, PROC GLIMMIX and PROC 
NLMIXED in SAS statistical software version 9.2. For the correlation between changes 
in objective VMS and changes in memory performance, we propose to examine the 
correlation between frequency of total objective VMS and verbal learning by conducting 
Pearson correlations to examine associations between changes in cognitive performance 
and changes in VMS. We will conduct partial correlations to examine whether these 
associations remained significant after controlling for changes in sleep quality (PSQI and 
actigraphy-based measures).
11.2
Provide a power analysis, if necessary.
A sample size of 18 in each treatment group will provide at least 80% power to test the 
two-way interaction between Treatment and Time with a significance level set at 0.05.
IRB #: STU00200390 Approved by NU IRB for use on or after 3/4/2019 through 3/3/2020.

Title:  SGB CA Study
Version August 3, 2018 
Page 16 of 28
Revised Template: November 10, 2014
We will need to screen and enroll approximately 50 women to randomize 36 women. 
Some women may not qualify due to insufficient number of hot flashes or there may 
be some withdrawals.   
11.3
Describe the steps that will be taken to secure the data to maintain 
confidentiality (e.g., training, authorization of access, password protection, encryption, 
physical controls, certificates of confidentiality, and separation of identifiers and data) 
during storage, use, and transmission
Research files and case report forms will be stored in the research offices of Dr. Walega 
and will be kept in locked offices with access only to the research team. Wherever 
possible, subject data will be stored using only the study ID. Measures will be taken to 
protect all personal information and data, including keeping all data sheets under lock and 
key and entering data into a database that requires login identification and a password 
made available only to immediate study personnel. The entire study team has taken the 
CITI training and is familiar with confidentiality requirements and procedures. 
Downloaded data from the Biolog hot flash monitor and the actigraph watch will be 
processed, stored, and analyzed in password-protected network at the University of 
Illinois in Chicago of Dr. Pauline Maki. Data related to cognitive assessments will be 
stored and analyzed at the University of Illinois at Chicago in Dr. Maki's lab. 
11.4
Describe any procedures that will be used for quality control of collected data
A computer-generated 1:1 block randomization scheme will be used to assign 
participants to receive either a SGB with bupivacaine or a sham injection with saline. 
Randomization will be performed by Dr. Walega immediately before the injection 
procedure by opening an opaque envelope to reveal the participant number and group 
assignment printed on an index card. Randomization assignment will be kept under lock 
and key. Participants and all other study personnel, including those who will perform 
follow-up evaluations, will be blinded to group assignment. To ensure that Dr. Walega’s 
knowledge of randomization assignments does not influence study results, he will have 
no additional follow up or interaction with study participants, unless an adverse event 
occurs that requires his immediate attention. The study team will be briefed on the types 
of adverse events that require his attention. Dr. Walega will not be involved in the 
collection of any primary or secondary data outcome.
11.5 Describe how data and specimens will be handled study-wide: see Section 11.0 
Data and Specimen Management
11.6 What information will be included in that data or associated with the       
specimens?
 See Section 11.0 Data and Specimen Management

Where and how data or specimens will be stored?
See Section 11.0 Data and Specimen Management

How long the data or specimens will be stored?
IRB #: STU00200390 Approved by NU IRB for use on or after 3/4/2019 through 3/3/2020.

Title:  SGB CA Study
Version August 3, 2018 
Page 17 of 28
Revised Template: November 10, 2014
Data will be stored indefinitely.

Who (role on the study) will have access to the data or specimens?
See Section 11.0 Data and Specimen Management

Who (role on the study) is responsible for receipt or transmission of 
the data or specimens? 
Dr. Walega at NU and Dr. Maki at UIC are responsible for the receipt or transmission of 
data. They may designate a member of the research team to transmit data in accordance 
with NU/UIC IT security policies.

How data and specimens will be transported?
See Section 11.0 Data and Specimen Management
Provisions to Monitor the Data to Ensure the Safety of Subjects
11.5
Describe:

The plan to periodically evaluate the data collected regarding both 
harms and benefits to determine whether subjects remain safe.  The plan might include 
establishing a data monitoring committee and a plan for reporting data monitoring 
committee findings to the IRB and the sponsor.
The study team will meet and review all adverse events after five subjects have been 
randomized and received the SGB procedure or sham. Per NU IRB protocol, all 
UPIRSO's or PRNCs will be reported a soon as the PI becomes aware of it. As the PI is 
the injectionist, the likelihood of missing a UPIRSO is highly unlikely. If no 
SAEs/UPIRSO's are observed, the team will meet again after 10 subjects have been 
randomized. No UPIRSOs or SAEs have occurred in previous studies. 

What data are reviewed, including safety data, untoward events, and 
efficacy data?
Participants who undergo the SGB with bupivacaine will experience a temporary 
sympathetic block of the right upper extremity and right face. Efficacy of the SGB will be 
confirmed by the presence of Horner’s syndrome (miosis, abnormal contraction of the 
pupil; ptosis, drooping upper eyelid; and anhydrosis ,absence of facial sweat) and a 
temperature increase of the affected extremity, the latter the result of regional 
venodilation. The temperature of the right upper extremity will be monitored prior to and 
30 minutes following the injection to confirm, along with a Horner’s syndrome, 
successful SGB. These events are expected and confirm correct SGB placement. Events 
outside of those expected are what will be reviewed as stated above. The study team will 
be trained on the types of study related SAEs or AEs that should immediately be reported 
to the PI/IRB since they will not have access to the procedures records to maintain the 
blind. 

How the safety information will be collected 
Safety data will be collected with case report forms, at study visits, and by telephone calls 
with participant.

The frequency of data collection, including when safety data 
collection starts.
IRB #: STU00200390 Approved by NU IRB for use on or after 3/4/2019 through 3/3/2020.

Title:  SGB CA Study
Version August 3, 2018 
Page 18 of 28
Revised Template: November 10, 2014
Safety data is collected as soon as the participant agrees to participate and signs the 
informed consent document. 

Who will review the data?
The PI will review the data with the study coordinator.

The frequency or periodicity of review of cumulative data.
Efficacy data will be reviewed at the conclusion of the study. Safety data will be 
reviewed after 5 are randomized, then after 10 are randomized. Thereafter, safety data 
will be reviewed every 6 months provided that no UPIRSOs are observed in those that 
have received the study procedure. 

The statistical tests for analyzing the safety data to determine 
whether harm is occurring.
No statistical test will be used to determine whether harm is occurring. There is a 
preponderance of safety information on the SGB procedure that is familiar to the PI as 
this is his area of expertise. If the PI determines that unexpected SAEs and AEs are 
occurring in the SGB which is higher than seen in clinical practice, he will immediately 
cease enrollment and notify the IRB.

Any conditions that trigger an immediate suspension of the research.
A participant study related death will trigger an immediate suspension of the research.
12.0
Withdrawal of Subjects*
12.1
Describe anticipated circumstances under which subjects will be withdrawn 
from the research without their consent, including stopping participation for safety 
reasons.
The PI can remove subjects from the research study without their approval. Possible 
reasons for removal include the following: if it appears to be medically harmful to the 
subject, or if they fail to follow directions for participating in the study, such as taking 
excluded medication (aspirin, anti-coagulants) prior to the SGB procedure, if it is later 
discovered that they did not meet the study eligibility requirements, at the discretion of 
the study doctor or, if the study is canceled.
12.2
Describe any procedures for orderly termination.
A subject who withdraws will be schedule to return to the research office. At this time, 
written diaries will be collected and AEs will be assessed, if any. Prior to scheduling the 
appointment, the subject will be asked if she would like to see the PI. If yes, this will be 
done on the same visit. If a subject does not wish to return, she will be asked to mail or 
fax any written diaries. Final payment will be mailed to the subject if compensation has 
not already been paid out.
12.3
Describe procedures that will be followed when subjects withdraw from the 
research, including partial withdrawal from procedures with continued data collection.
Subjects only have the option of not participating in the cognition study. All other 
procedures are required as part of the study. The subject has the option to withdraw if she 
does not want to participate in the hot flash monitoring, actigraph monitoring and most 
importantly, maintaining a written diary for the duration of the study.
13.0
Risks to Subjects*
13.1
List the reasonably foreseeable risks, discomforts, hazards, or inconveniences to 
the subjects related the subjects’ participation in the research. Include as may be useful 
for the IRB’s consideration, describe the probability, magnitude, duration, and 
IRB #: STU00200390 Approved by NU IRB for use on or after 3/4/2019 through 3/3/2020.

Title:  SGB CA Study
Version August 3, 2018 
Page 19 of 28
Revised Template: November 10, 2014
reversibility of the risks. Consider physical, psychological, social, legal, and economic 
risks.
There are risks associated with participation in this study. Below is a description of the 
risks:
Stellate Ganglion Block with local anesthetic 
Stellate ganglion injection carries the potential very rare risk of infection at the injection 
site, bleeding or blood clot formation at the injection site, seizures (sudden, uncontrolled 
muscle spasms and loss of consciousness) and nerve injury which may present as 
temporary parasthesia (numbness) and/or weakness.  All of these rare risks are minimized 
with the use of fluoroscopic guidance (visualization with a type of x-ray). Other 
complications related to the stellate ganglion injection that can occur are puncture of the 
lung on the right during placement of the needle on the right neck, or an allergic reaction 
to the medications being injected into the subject. Temporary voice hoarseness, 
temporary mild shortness of breath, temporary difficulty swallowing, and temporary 
changes in your blood pressure may occur after the stellate ganglion injection from the 
numbing medicine.  Possible reactions from the numbing medicine used in this study last 
6-8 hours.   Minor soreness at the injection site could last 1-2 days.
Tissue injection of saline (sham) below the surface of the skin
Needle placement carries the potential very rare risk of infection at the injection site, 
bleeding or blood clot formation at the injection site, temporary swelling of the right side 
of the neck from the injected liquid and an allergic reaction to the medications being 
injected into you.  Minor soreness at the injection site could last 1-2 days.  
Risk of Radiation from the x-ray
The cumulative radiation exposure from these tests is considered small and is not likely 
to adversely affect the subject or their disease.
The contact with radiation in this study is thought to be small. However, the effects of 
radiation add up over a lifetime. It is possible that having several of these X-rays may add 
to the subject's risk of injury or disease. When deciding to enter this study, subjects will 
be asked to consider past and future contact with radiation. Examples of contact with 
radiation include x-rays or CT scans taken for any reason or radiation therapy for cancer 
treatment. 
Risks from the hot flash monitor 
The hot flash monitor does not involve significant risk. Wearing the monitor can be a 
minor inconvenience. The monitor poses no risk of electric shock. Potential side effects 
of the monitor include (1) allergy to the paper or adhesive on the disposable electrodes 
(minor, 1%), (2) itching at the site of electrode attachment (minor, 4%) and (3) 
discoloration of the skin from the electrode gel. 
IRB #: STU00200390 Approved by NU IRB for use on or after 3/4/2019 through 3/3/2020.

Title:  SGB CA Study
Version August 3, 2018 
Page 20 of 28
Revised Template: November 10, 2014
Risks with the Actigraph watch 
The Actigraph watch does not involve significant risk. Wearing the watch can be a minor 
inconvenience, and the band may cause slight irritation.
Questionnaires
Being in this study may make the subject feel emotionally uncomfortable. They might 
feel anxious, or experience emotional reactions to some of the questions that will be 
asked
Cognitive Testing
Subjects may find some of the cognitive tests to be challenging, frustrating, or boring. 
Confidentiality Risks
There is a risk of loss of confidentiality. Certain measures are taken to protect all personal 
information and data, including keeping all data sheets under lock and key and entering 
data into a non-network database that requires a login id and password made available 
only to immediate study personnel.
13.2
If applicable, indicate which procedures may have risks to the subjects that are 
currently unforeseeable.
Currently, there are no unforeseeable risks to the study procedures.
14.0
Potential Benefits to Subjects
14.1
Describe the potential benefits that individual subjects may experience from 
taking part in the research. Include as may be useful for the IRB’s consideration, the 
probability, magnitude, and duration of the potential benefits.
Possible benefits include a reduction in the severity or frequency of hot flashes, an 
improvement in overall feeling of well-being and ability to perform the functions of daily 
living impacted by hot flashes. We do not know how long these benefits will last.
14.2
Indicate if there is no direct benefit. Do not include benefits to society or others.
Subjects who receive the sham procedure will have no direct benefit from participation.
15.0
Vulnerable Populations -N/A
16.0
Community-Based Participatory Research-N/A
Sharing of Results with Subjects
16.1
Describe whether results (study results or individual subject results, such as 
results of investigational diagnostic tests, genetic tests, or incidental findings) will be 
IRB #: STU00200390 Approved by NU IRB for use on or after 3/4/2019 through 3/3/2020.

Title:  SGB CA Study
Version August 3, 2018 
Page 21 of 28
Revised Template: November 10, 2014
shared with subjects or others (e.g., the subject’s primary care physicians) and if so, 
describe how it will be shared.
Study results will not be shared with subjects as they are considered experimental and are 
not required or related to their on-going medical care.
17.0
Setting
17.1
Describe the sites or locations where your research team will conduct the 
research.
Northwestern Medicine, formerly the Northwestern Medical Faculty Foundation, 
maintains a dedicated Pain Medicine Center located in the Galter Pavilion at the 
Northwestern University Chicago campus. The stellate ganglion blockade or sham 
injection will take place at this facility.
Consenting, questionnaire completion and cognition testing will take place in the research 
office of Dr. Walega at 633 N St Clair, suite 1800 or 1876 N St Clair, Arkes Pavilion, 
Department of Anesthesia. 

Identify where your research team will identify and recruit potential 
subjects.
IRB approved flyers, physician provider letters and internet notices will be utilized for 
the study. See "Supporting Documents" section. We expect that potential subjects will 
contact the research office as a result of the recruitment aids or will be referred to us by 
health providers.
18.0
Resources Available
18.1
Describe the qualifications (e.g., training, experience, and oversight) of you and 
your staff as required to perform their role. When applicable describe their knowledge 
of the local study sites, culture, and society. Provide enough information to convince 
the IRB that you have qualified staff for the proposed research. You do not need to list 
individual names of your staff in this protocol.
Dr. Walega has the full and expressed support of his department Chair, Dr. Christine 
Stock, to successfully pursue this study. The Department of Anesthesiology and 
Northwestern University supported Dr. Walega's pursuit of a Master of Science in 
Clinical Investigation at Northwestern University through direct financial support. This is 
a rigorous program designed to enhance a clinician's ability to design and successfully 
execute clinical research studies and seek grant support for such studies. He successfully 
earned this degree while working full time as a Division Chief and a fellowship Program 
Director.
Dr. Shulman is a Professor of Obstetrics and Gynecology at Northwestern University, the 
Director of the Ovarian Cancer Early Detection and Prevention Program and Co-Director 
of Cancer Genetics Program at Northwestern. He will serve as Co-investigator for this 
study. His role as the Co-Director of the cancer genetics program allows him to interface 
with the team in facilitating recruitment for women with breast cancer with moderate to 
severe hot flashes. 
IRB #: STU00200390 Approved by NU IRB for use on or after 3/4/2019 through 3/3/2020.

Title:  SGB CA Study
Version August 3, 2018 
Page 22 of 28
Revised Template: November 10, 2014
Pauline M. Maki, PhD, is Professor of Psychiatry and Psychology at UIC and Director of 
the Women’s Mental Health Research Program. She will oversee all research activities 
performed by UIC personnel, which center on the collection, scoring, management, and
interpretation of secondary outcome measures: neurocognitive outcomes, objective hot 
flash monitoring, and actigraphy (sleep).
 Ms. Banuvar is a Clinical Research Associate and has a long history of collaboration 
with Dr. Maki and Dr. Shulman and has worked on three projects related to vasomotor 
symptoms with her team. She will be responsible for data integrity and protocol 
maintenance. She will monitor the data and subject hot flash data collection of subjects.
She will assist the PI in monitoring and reporting adverse events as well as 
correspondence with NU IRB. 
18.2
Describe other resources available to conduct the research: For example, as 
appropriate:
At UIC under the supervision of Dr. Maki, all computers have access to a secure server 
which is accessed through a unique IT department provided log-in. All electronic data are 
stored on the secure server. Only delegated logins have the ability to view or edit the 
information stored in on this server. Currently two of the 10 computers are equipped with 
a Biolog Transfer box, Biolog DPS software (for downloading and convert Biolog data) 
and Biolog 3.7, the most recent version of the software used to score and edit the Biolog 
data. Eight computers are currently equipped with the Actiware software (version 5.7) 
which is used to configure, download and score Actiwatch data. The downloading 
platform can be moved between computers as needed.

Justify the feasibility of recruiting the required number of suitable 
subjects within the agreed recruitment period. For example, how many potential 
subjects do you have access to? What percentage of those potential subjects do you 
need to recruit?
Based on our experience with previous studies, we estimate we would need to screen 50 
women to randomized 36 women. This is a small sample size. We do not anticipate 
problems in obtaining  a complete sample size over the next year.

Describe the time that you will devote to conducting and completing 
the research. (Note: This description is intended to provide the IRB with information 
relative to conduct of the study as relevant for the protection of research subjects, not 
for effort reporting.)
We anticipate that the study team will contribute 2.5 days per week to the project.

Describe your facilities. (Note: This description is intended to 
provide the IRB with information relative to conduct of the study as relevant for the 
protection of research subjects, not for Facilities and Administration considerations.)
Already addressed in Section 17.0 and 18.0.

Describe the availability of medical or psychological resources that 
subjects might need as a result of an anticipated consequences of the human research.

Describe your process to ensure that all persons assisting with the 
research are adequately informed about the protocol, the research procedures, and 
their duties and functions.
IRB #: STU00200390 Approved by NU IRB for use on or after 3/4/2019 through 3/3/2020.

Title:  SGB CA Study
Version August 3, 2018 
Page 23 of 28
Revised Template: November 10, 2014
Prior to the inception of the study and after IRB approval has been obtained, the research 
team will meet to review the protocol. Safety endpoints will be reviewed and study 
logistics will be coordinated and agreed upon. 
   
19.0
Prior Approvals
19.1
Describe any approvals that will be obtained prior to commencing the research. 
We will obtain radiation safety by means of the Radiation Dosimetry Form.
20.0
Recruitment Methods
20.1
Describe when, where, and how potential subjects will be recruited.
IRB approved flyers, physician provider letters and internet notices will be utilized for 
the study. See "Supporting Documents" section. We expect that potential subjects will 
contact the research office as a result of the recruitment aids or will be referred to us by 
health providers. Subjects will be asked to come to the research office for consenting if 
they are interested in the study. 
20.2
Describe the source of subjects.
We expect that the majority of subjects will come from the practices of Northwestern 
Medicine providers.
20.3
Describe the methods that will be used to identify potential subjects.
IRB approved flyers, physician provider letters and internet notices will be utilized for 
the study. See "Supporting Documents" section.
20.4
Describe materials that will be used to recruit subjects. (Attach copies of these 
documents with the eIRB+ application. For advertisements, attach the final copy of 
printed advertisements. When advertisements are taped for broadcast, attach the final 
audio/video file. You may submit the wording of the advertisement prior to taping to 
preclude re-taping because of inappropriate wording, provided the IRB reviews the 
final audio/video file.)
See "Supporting Documents" section.
20.5
Describe the amount, timing, and method of any payments to subjects. (E.g., 
Gift card, Clinker, check.)
The study will pay for parking in the hospital parking lot located on St. Clair St., between 
Superior and Huron Streets. Their parking ticket will be validated by the research staff 
and paid for up to six hours.
Subjects who agree to take part in this research study, will be paid $200.00 by check at 
study completion for time and effort. If they agree to collect hot flash data for an 
additional six months after completion of the study, they will be paid an additional  
$100.00 if they complete a written diary for each of the six months. They may choose to 
have the final check mailed to them, or they may come to the clinic to retrieve their check 
if that is more convenient.
IRB #: STU00200390 Approved by NU IRB for use on or after 3/4/2019 through 3/3/2020.

Title:  SGB CA Study
Version August 3, 2018 
Page 24 of 28
Revised Template: November 10, 2014
21.0
Local Number of Subjects
21.1
Indicate the total number of subjects to be accrued locally 36
21.2
If applicable, include a break-down of subjects by study location or procedure 
group 15 women will be in the SGB procedure group and 18 women will be in the sham 
group. All women will be recruited and followed at Northwestern.
21.3
If applicable, distinguish between the number of subjects who are expected to 
be enrolled and screened, and the number of subjects needed to complete the research 
procedures (i.e., numbers of subjects excluding screen failures.)
Thirty enrolled subjects are required to complete the study. We estimate that we would 
need to screen approximately sixty women to randomize thirty women.
22.0
Confidentiality-Repetitive 
These issues have already been addressed in the Data and Specimen Management Section 
11.3 to 11.4.
22.1
If this is a multicenter study, describe the local procedures for maintenance of 
confidentiality.

Where and how data or specimens will be stored locally?

How long the data or specimens will be stored locally?

Who will have access to the data or specimens locally?

Who is responsible for receipt or transmission of the data or 
specimens locally?

How data and specimens will be transported locally?

23.0
Provisions to Protect the Privacy Interests of Subjects
23.1
Describe the steps that will be taken to protect subjects’ privacy interests. 
“Privacy interest” refers to a person’s desire to place limits on with whom they interact 
or to whom they provide personal information.
Potential subjects do not have to authorize the use or disclosure of their health 
information; however, they will not be allowed to take part in this research study. They 
may also revoke authorization for use or disclosure of their health information in writing. 
Direct personal identifiers will not be used in the database. In addition, unless disclosure 
of the direct identifier is necessary for review by regulatory authorities or is required by 
law, access to direct identifiers will be strictly limited to research team delegates of the 
PI. 
23.2
Describe what steps you will take to make the subjects feel at ease with the 
research situation in terms of the questions being asked and the procedures being 
performed. “At ease” does not refer to physical discomfort, but the sense of 
intrusiveness a subject might experience in response to questions, examinations, and 
procedures.
Subjects will be reassured that if there are questions in the surveys that they do not want 
to answer or if some of the questions make them uncomfortable, they do not have to 
IRB #: STU00200390 Approved by NU IRB for use on or after 3/4/2019 through 3/3/2020.

Title:  SGB CA Study
Version August 3, 2018 
Page 25 of 28
Revised Template: November 10, 2014
answer them. In addition, if they have questions or concerns about the study procedures 
the research team, including the PI, is available to them for the duration of the study . 
They will be told that they do not have to wait for study related clinic visits  to be seen or 
assessed for any concern.
23.3
Indicate how the research team is permitted to access any sources of 
information about the subjects. (E.g., What permission does the research staff have to 
access medical records or other sensitive information?)
HIPAA Authorization will be obtained from all research subjects through the consent 
document. Subjects will give us the permission to use personal health information that 
includes health information in the medical records and information that can identify 
them. Personal health information may include the subject's name, address, phone 
number or social security number. Health information we may collect and use for this 
research includes: 

All information in a medical record 

Results of physical examinations

Medical history

Lab tests, or certain health information indicating or relating to a particular 
condition as well diaries and questionnaires

Records about study medication or drugs

Substance abuse information: current substance abuse is an exclusion to 
participation in the study

Mental Health information: history of depression, psychosis and concomitant 
medication

Dr. Pauline Maki from The University of Illinois at Chicago, Department of 
Psychiatry and her research assistants working directly under her supervision,  
may also receive, or use health information. The reason for sharing this  data with 
these individuals is that UIC personnel may be involved in the collection of hot 
flash data, actigraph data. Questionnaire data and cognitive test results.
24.0
Compensation for Research-Related Injury
24.1
If the research involves more than Minimal Risk to subjects, describe the 
available compensation in the event of research-related injury.
Subjects who need medical care because of taking part in this research study may seek 
medical treatment through the investigator or a treatment center of their choice.  The care 
will be billed to the subject, or their insurance. The study has no program to pay for 
medical care for research-related injury.
24.2
Provide a copy of contract language, if any, relevant to compensation for 
research-related injury. N/A
25.0
Economic Burden to Subjects
IRB #: STU00200390 Approved by NU IRB for use on or after 3/4/2019 through 3/3/2020.

Title:  SGB CA Study
Version August 3, 2018 
Page 26 of 28
Revised Template: November 10, 2014
25.1
Describe any costs that subjects may be responsible for because of participation 
in the research.
There are no costs to the subject for participation in the research.
26.0
Consent Process
26.1
Indicate whether you will you be obtaining consent, and if so describe:
Written informed consent will be obtained from every subject.

Where will the consent process take place
Consent will take place in the research office of Dr. Walega and his team.

Any waiting period available between informing the prospective 
subject and obtaining the consent.
The waiting period available is solely at the discretion of the participant. If the subject 
learns of the study via a flyer or provider and telephones the research office, the subject 
will be asked to present to the research office in order for written informed consent to be 
obtained in person. Alternatively, if the subject learns of the study in a clinical setting, if 
the research team is available and if a private space is available, the team member can go 
to the subject to conduct the informed consent process and obtain written consent.

Any process to ensure ongoing consent.
The PI will again ask the subject prior to administration of the study procedure whether 
they have had any additional questions or concerns and whether they still wish to 
continue their participation.

Whether you will be following “SOP: Informed Consent Process for 
Research (HRP-090).” If not, describe:
“SOP: Informed Consent Process for Research (HRP-090)” will be followed for this 
study.
o
The role of the individuals listed in the application as being 
involved in the consent process.
o
The time that will be devoted to the consent discussion.
The discussion will take as long as is needed to insure that the subject has fully read the 
document and expresses understanding. For this study, we plan to allow 1 hour for the 
consent discussion but it may be extended if needed.
o
Steps that will be taken to minimize the possibility of coercion 
or undue influence.
o
Although Dr. Walega will be overseeing the consent process, he 
will not be directly obtaining consent. It is unlikely that these study patients will be ones 
he may be treating in his Pain Clinic so there would likely be no concern for undue 
influence as the treating physician.
o
Steps that will be taken to ensure the subjects’ 
understanding.
Individuals involved in the consent process will dialogue with the subject to insure they 
understand what is required. They may be asked to summarize their understanding of the 
goals and procedures of the study. Care will be given to ensure they do not feel like they 
are being "tested".
Non-English Speaking Subject-NA
IRB #: STU00200390 Approved by NU IRB for use on or after 3/4/2019 through 3/3/2020.

Title:  SGB CA Study
Version August 3, 2018 
Page 27 of 28
Revised Template: November 10, 2014
Waiver or Alteration of Consent Process (consent will not be obtained, required 
information will not be disclosed, or the research involves deception)-N/A
Subjects who are not yet adults (infants, children, teenagers) -N/A.
Cognitively Impaired Adults-N/A
Adults Unable to Consent-N/A
27.0
Process to Document Consent in Writing
27.1
Describe whether you will be following “SOP: Written Documentation of 
Consent (HRP-091).” If not, describe whether and how consent of the subject will be 
documented in writing.
“SOP: Written Documentation of Consent (HRP-091)” will be followed for this study.
27.2
If you will document consent in writing, attach a consent document in your 
eIRB+ application. 
Consent document is included in Supporting Documents Section.
28.0
Drugs or Devices
28.1
If the research involves drugs or devices, describe your plans to store, handle, 
and administer those drugs or devices so that they will be used only on subjects and be 
used only by authorized investigators.
Dr. Walega will be solely responsible for administering the drugs to be used in this study. 
They will be stored in the Pain Clinic as these drugs are typically used as part of the 
standard of care for SGB and other clinic procedures.
28.2
If the drug is investigational (has an IND) or the device has an IDE or a claim 
of an abbreviated IDE (non-significant risk device), include the following information: 
N/A
Literature
1.Carpenter JS, Johnson D, Wagner L, Andrykowski M. Hot flashes and related 
outcomes in breast cancer survivors and matched comparison women. Oncology Nursing 
Forum. 2002; 29(3): E16-25.
2.Gupta P, Sturdee DW, Palin SL, Majumder K, Fear R, Marshall T, et al. Menopausal 
symptoms in women treated for breast cancer: the prevalence and severity of symptoms 
and their perceived effects on quality of life. Climacteric. 2006; 9(1): 49-58.
3.Land SR, Wickerham DL, Costantino JP, Ritter MW, Vogel VG, Lee M, et al. Patient-
reported symptoms and quality of life during treatment with tamoxifen or raloxifene for 
breast cancer prevention: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 
trial. JAMA. 2006; 295(23): 2742-51.
4.Hunter MS, Grunfeld EA, Mittal S, Sikka P, Ramirez AJ, Fentiman I, et al. Menopausal 
symptoms in women with breast cancer: prevalence and treatment preferences. 
Psychooncology. 2004; 13;769-78.
IRB #: STU00200390 Approved by NU IRB for use on or after 3/4/2019 through 3/3/2020.

Title:  SGB CA Study
Version August 3, 2018 
Page 28 of 28
Revised Template: November 10, 2014
5.Baber R, Hickey M, Kwik M. Therapy for menopausal symptoms during and after 
treatment for breast cancer : safety considerations. Drug Saf. 2005; 28(12): 1085-100.
6.Hickey M, Saunders CM, Stuckey BG. Management of menopausal symptoms in 
patients with breast cancer: an evidence-based approach. Lancet Oncol. 2005; 6(9): 687-
95.    
7. Cella D, Fallowfield LJ. Recognition and management of treatment-related side effects 
for breast cancer patients receiving adjuvant endocrine therapy. Breast Cancer Res Treat. 
2008; 107(2): 167-80.
8.Pachman DR, Barton D, Carns PE, Novotny PJ, Wolf S, Linquist B, et al. Pilot 
evaluation of a stellate ganglion block for the treatment of hot flashes. Supportive Care in 
Cancer. 2011; 19(7): 941-7.
9.Lipov EG, Joshi JR, Sanders S, Wilcox K, Lipov S, Xie H, et al. Effects of stellate-
ganglion block on hot flushes and night awakenings in survivors of breast cancer: a pilot 
study. Lancet Oncol. 2008; 9: 523-32.
10.Haest K, Kumar A, Van Calster B, Leunen K, Smeets A, Amant F, et al. Stellate 
ganglion block for the management of hot flashes and sleep disturbances in breast cancer 
survivors: an uncontrolled experimental study with 24 weeks of follow-up. Annals of 
Oncology. 2012; 23(6): 1449-54.
11. Walega DR, Maki PM, Rubin LH, Banuvar S, Shulman LP.  Effects of Stellate 
Ganglion Blockade on Vasomotor Symptoms: Findings from a Randomized Clinical 
Trial of Postmenopausal Women. Menopause Aug 2014 PMID 24496086 
12. Maki PM, Rubin LH, Savarese A, Walega DR, Banuvar S, Shulman LP. Reductions 
in Vasomotor Symptom Following Stellate Ganglion Blockade are Related To 
Improvements in Memory.  Maturitas 2014 (accepted for publication)
13. Wulf H, Maier C. Complications and side effects of stellate ganglion blockade. 
Results of a questionnaire survey. Anaesthesist. 1992; 41(3): 146-51.
14. Otthman AH, Zaky AH. Management of Hot Flushes in Breast Cancer Survivors: 
Comparison between Stellate ganglion Block and Pregabalin.
15. Guttuso T. Stellate ganglion block for treating hot flashes: a viable option or sham 
procedure? Maturitas 2013; 76:221-224.
16. Walega DR, Maki PM. Letter to the Editor:  Effects of Stellate Ganglion Blockade on 
Vasomotor Symptoms: Findings from a Randomized Clinical Trial of Postmenopausal 
Women. Menopause 2014. PMID 24937028
IRB #: STU00200390 Approved by NU IRB for use on or after 3/4/2019 through 3/3/2020.